Abstract:ABSTRACT Vibrio cholerae secretes cholera toxin (CT) and the closely related heat-labile enterotoxin (LT) of Escherichia coli , the latter when expressed in V. cholerae . Both toxins are also potent immunoadjuvants. Mutant LT molecules that retain immunoadjuvant properties while possessing markedly diminished enterotoxic activities when expressed by E. coli have been developed. One such mutant LT molecule has the substitution of a glycine residue for arginine-192 [LT (R192G) ]. Live attenuated strains of V. cholerae that have been used both as V. cholerae vaccines and as vectors for inducing mucosal and systemic immune responses directed against expressed heterologous antigens have been developed. In order to ascertain whether LT (R192G) can act as an immunoadjuvant when expressed in vivo by V. cholerae , we introduced a plasmid (pCS95) expressing this molecule into three vaccine strains of V. cholerae , Peru2, ETR3, and JRB14; the latter two strains contain genes encoding different heterologous antigens in the chromosome of the vaccine vectors. We found that LT (R192G) was expressed from pCS95 in vitro by both E. coli and V. cholerae strains but that LT (R192G) was detectable in the supernatant fraction of V. cholerae cultures only. In order to assess potential immunoadjuvanticity, groups of germfree mice were inoculated with the three V. cholerae vaccine strains alone and compared to groups inoculated with the V. cholerae vaccine strains supplemented with purified CT as an oral immunoadjuvant or V. cholerae vaccine strains expressing LT (R192G) from pCS95. We found that mice continued to pass stool containing V. cholerae strains with pCS95 for at least 4 days after oral inoculation, the last day evaluated. We found that inoculation with V. cholerae vaccine strains containing pCS95 resulted in anti-LT (R192G) immune responses, confirming in vivo expression. We were unable to detect immune responses directed against the heterologous antigens expressed at low levels in any group of animals, including animals that received purified CT as an immunoadjuvant. We were, however, able to measure increased vibriocidal immune responses against vaccine strains in animals that received V. cholerae vaccine strains expressing LT (R192G) from pCS95 compared to the responses in animals that received V. cholerae vaccine strains alone. These results demonstrate that mutant LT molecules can be expressed in vivo by attenuated vaccine strains of V. cholerae and that such expression can result in an immunoadjuvant effect.

Expression of Cholera Toxin B–Lumbrokinase Fusion Protein in Pichia Pastoris —the Use of Transmucosal Carriers in the Delivery of Therapeutic Proteins to Protect Rats Against Thrombosis

Reconstruction of the Heat-Labile Enterotoxin Subunit B Gene of Escherichia Coli and Its Immune Adjuvant Activity on Mucosa

Intracellular and Extracellular Expression of Bacillus Thuringiensis Crystal Protein Cry5B in Lactococcus Lactis for Use As an Anthelminthic.

Expression, purification, and characterization of recombinant lumbrokinase PI239 in Escherichia coli.

Determination of fbe mucosal immunoadjuvantivity of recombinant EschericMa cott LTKA63 mutant and LTB

Cholera toxin and cholera B subunit as oral—mucosal adjuvant and antigen vector systems

A potential delivery system based on cholera toxin: A macromolecule carrier with multiple activities

In Vivo Expression and Immunoadjuvancy of a Mutant of Heat-Labile Enterotoxin of Escherichia coli in Vaccine and Vector Strains of Vibrio cholerae

In-Depth Characterization of a Re-Engineered Cholera Toxin Manufacturing Process Using Growth-Decoupled Production in Escherichia coli

Enhancement of the mucosal immune responses and prophylactic effect of a novel coxsackievirus B3-specific mucosal DNA vaccine by co-administration of lymphotactin

Enhanced delivery of protein therapeutics with a diphtheria toxin-like platform that evades pre-existing neutralizing immunity

The use of Bacillus subtilis as a cost-effective expression system for production of Cholera Toxin B fused factor VIII epitope regions applicable for inducing oral immune tolerance

Secretory expression of a heterologous nattokinase in Lactococcus lactis

Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa

Surface Display of Cholera Toxin B Subunit Recombinant Escherichia coli Ghosts Further Enhances Resistance to Chlamydia abortus Infection in Mice

Enhanced gastrointestinal survivability of recombinant Lactococcus lactis using a double coated mucoadhesive film approach

Cholera Toxin Subunit B Enabled Multifunctional Glioma-Targeted Drug Delivery.

Plasmid Vectors Encoding Cholera Toxin or the Heat-Labile Enterotoxin from Escherichia coli Are Strong Adjuvants for DNA Vaccines

Cholera Toxin Subunit B as Adjuvant––An Accelerator in Protective Immunity and a Break in Autoimmunity

Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses